Enlivex Therapeutics Ltd. Announces Proposed Offering of Ordinary Shares
November 20 2019 - 4:14PM
Enlivex Therapeutics Ltd. (“Enlivex” or the “Company”)
(NASDAQ:ENLV) today announced that, subject to market and other
conditions, it intends to offer and sell ordinary shares (the
“Shares”) in an underwritten public offering. The Company intends
to grant the underwriter an option for a period of 45 days to
purchase up to an additional 15 percent of the number of Shares to
be issued and sold in the public offering solely to cover
over-allotments, if any.
The Company intends to use the net proceeds received from the
offering of the Shares for clinical, regulatory, manufacturing
and research and development activities, potential
acquisitions and in-licensing, and other general corporate
purposes.
Aegis Capital Corp. will act as sole book-runner for the
offering.
The offering of the Shares will be made by means
of a prospectus supplement to the prospectus forming a part of the
Company’s effective shelf registration statement on Form F-3
(Registration No. 333-232009) filed with the Securities and
Exchange Commission (the “SEC”) on June 7, 2019 and other related
documents. You may obtain these documents for free by visiting
EDGAR on the SEC website at www.sec.gov. Alternatively, copies of
the preliminary prospectus supplement may be obtained from Aegis
Capital Corp., Attention: Prospectus Department, 810 7th Avenue,
18th floor, New York, NY 10019, by email at syndicate@aegiscap.com,
or by telephone at (212) 813-1010 . Before you invest, you should
read the prospectus supplement and the accompanying base prospectus
along with other documents that the Company has filed with the SEC
for more complete information about the Company and this
offering.
This press release shall not constitute an offer to sell, or a
solicitation of an offer to buy, the Shares or any other
securities, nor will there be any sale of the Shares or any other
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or other
jurisdiction.
About Enlivex
Enlivex is a clinical stage immunotherapy company, developing an
allogeneic drug pipeline for immune system rebalancing. Immune
system rebalancing is critical for the treatment of
life-threatening immune and inflammatory conditions which involve
hyper-expression of cytokines (Cytokine Release Syndrome) and for
which there are no approved treatments (unmet medical needs), as
well as solid tumors immune-checkpoint rebalancing.
Cautionary Statement Regarding Forward Looking
Statements
This press release contains forward-looking statements, which
may be identified by words such as "expects," "plans," "projects,"
"will," "may," "anticipates," "believes," "should," "would",
"could," "intends," "estimates," "suggests," "has the potential to"
and other words of similar meaning, including statements regarding
our ability to consummate the offering of Shares upon the
anticipated terms and timing, the intended use of proceeds
received from the offering of the Shares, expected cash balances,
market opportunities for the results of current clinical studies
and preclinical experiments, the effectiveness of, and market
opportunities for, ALLOCETRA™ programs. All such
forward-looking statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995. Investors are cautioned that forward-looking statements
involve risks and uncertainties that may affect Enlivex's business
and prospects, including the risks that Enlivex may not succeed in
generating any revenues or developing any commercial products; that
the products in development may fail, may not achieve the expected
results or effectiveness and/or may not generate data that would
support the approval or marketing of these products for the
indications being studied or for other indications; that ongoing
studies may not continue to show substantial or any activity; and
other risks and uncertainties that may cause results to differ
materially from those set forth in the forward-looking statements.
The results of clinical trials in humans may produce results that
differ significantly from the results of clinical and other trials
in animals. The results of early-stage trials may differ
significantly from the results of more developed, later-stage
trials. The development of any products using the
ALLOCETRA™ product line could also be affected by a number of
other factors, including unexpected safety, efficacy or
manufacturing issues, additional time requirements for data
analyses and decision making, the impact of pharmaceutical industry
regulation, the impact of competitive products and pricing and the
impact of patents and other proprietary rights held by competitors
and other third parties. In addition to the risk factors
described above, investors should consider the economic,
competitive, governmental, technological and other factors
discussed in Enlivex's filings with the SEC, including in the
Company's most recent Annual Report on Form 20-F filed with the
SEC. The forward-looking statements contained in this press
release speak only as of the date the statements were made, and we
do not undertake any obligation to update forward-looking
statements, except as required under applicable law.
Investors
Shachar Shlosberger, CFOEnlivex Therapeutics
Ltd.shachar@enlivexpharm.com
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Sep 2023 to Sep 2024